• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cue Biopharma, Inc. - Common Stock (NQ:CUE)

    0.7892 +0.0341 (+4.52%)
    Streaming Delayed Price Updated: 10:46 AM EDT, May 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cue Biopharma, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Strategic Organizational Transition
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Pricing of $12.0 Million Public Offering
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Proposed Public Offering
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Proposed Public Offering
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.